2 documents found, page 1 of 1
Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Co...
Steg, P. Gabriel; Szarek, Michael; Valgimigli, Marco; Islam, Shahidul; Zeiher, Andreas M.; Bhatt, Deepak L.; Bittner, Vera A.; Chiang, Chern-EnBackground Many patients require revascularization after index acute coronary syndrome (ACS). Lipoprotein(a) is thought to play a pathogenic role in atherothrombosis. In ODYSSEY OUTCOMES, alirocumab reduced major adverse cardiovascular events after ACS, with greater reduction among those with higher lipoprotein(a) levels. We explored whether risk of revascularization after ACS was modified by the level of lipop...
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation dev...
Hindricks, Gerhard; Potpara, Tatjana; Dagres, Nikolaos; Arbelo, Elena; Bax, Jeroen J.; Blomström-Lundqvist, Carina; Boriani, Giuseppe; Castella, ManuelAtrial fibrillation (AF) poses significant burden to patients, physicians, and healthcare systems globally. Substantial research efforts and resources are being directed towards gaining detailed information about the mechanisms underlying AF, its natural course and effective treatments (see also the ESC Textbook of Cardiovascular Medicine: CardioMed) and new evidence is continuously generated and published. The...